Folge 45 - Vom MRA bei schlechter Nierenfunktion und der Auswirkung von Adhärenz bei Lipidtherapie
Quellen:
Matsumoto S, Henderson AD, Shen L, Yang M, Swedberg K, Vaduganathan M, van Veldhuisen DJ, Solomon SD, Pitt B, Zannad F, Jhund PS, McMurray JJV. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function. J Am Coll Cardiol. 2024 Jun 18;83(24):2426-2436. doi: 10.1016/j.jacc.2024.03.426. Epub 2024 May 12. PMID: 38739064.
https://doi.org/10.1016/j.jacc.2024.03.426
Mazhar F, Hjemdahl P, Sjölander A, Kahan T, Jernberg T, Carrero JJ. Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention. Am Heart J. 2024 Mar;269:118-130. doi: 10.1016/j.ahj.2023.12.010. Epub 2023 Dec 16. PMID: 38109988.
https://doi.org/10.1016/j.ahj.2023.12.010
Create your
podcast in
minutes
It is Free